We are international
Donate

Research at ASH 2013 Points the Way Forward for Myeloma Patients

| 8 Comments
DurieBlog_ASHresearch.png
This year's annual meeting of the American Hematological Society (ASH) was truly exhausting, but especially exciting. So many abstracts, so little time!  One had to be a magician to cover major sessions running in parallel. Add to that the cold weather in New Orleans, travel delays, a vast, maze-like, conference center, and you end up with multiple 18-hour days.

But there was much to learn and the IMF's goal is to see the research results through the language and lens of science and point the way forward for patients towards better outcomes and a cure.

On the final evening, the IMF's Conference Series debate, "Making Sense of Treatment" went a long way to capturing the key outcomes from this year's ASH. Four topics were covered: Best Frontline Options; the Role of Maintenance; Minimal Residual Disease: Is This Important?; and New Drugs: Which Will Make an Impact?  The panel from our Stockholm Conference Series --- Doctors Antonio Palumbo, Ola Landgren, Joseph Mikhael and myself--returned to do battle again!

Best Frontline Options

The impact of novel therapies is clearly evident in the improved outcomes in the frontline setting. The panelists grappled with two main questions: How many drugs should be used in an ideal combination? And is carfilzomib (Kyprolis) now preferred over bortezomib (Velcade)? An important ancillary question  was whether or not treatment should change based upon the age or "fitness" of the patient, which is an important research interest for Antonio Palumbo.

Two drugs (Revlimid/low dose dexamethasone (Rd)) prevailed in the MM-020 trial presented at the plenary session. Rd as continuous therapy was superior for patients over age 65 years versus Rd for 18 months and MPT (Melphalan, prednisone, thalidomide) for 12 cycles- which is the standard, approved MPT protocol. So there was a clear vote for 2 drugs (Rd) in this elderly setting. But what about transplant eligible patients? 

Results with both Velcade and Kyprolis combinations as 3 drug combinations are really good. It was generally agreed that 3 drugs are enough (versus 4 or even 5 drug combinations) unless possibly one of the new monoclonal antibodies adds an important new mechanism of action.

Results incorporating either Revlimid (VRd or CRd) or Cytoxan (VCd [Cybord] or CRd) into the combinations are really excellent. But even higher percentage and deeper responses are clearly occurring with the Kyprolis combinations. 

So what did our experts have to say about all this? 

Joseph Mikhael felt that the longer term results with Cybord (Velcade/Cytoxan/dex), with, for example, 81% survival at 5 years in standard risk patients, justifies use of this regimen as a first step, especially since it is cost effective and well tolerated. Conversely, Ola Landgren indicated that CRd (carfilzomib/Revlimid/dex) gives higher and deeper responses, is well-tolerated even in the elderly and works well for both standard and higher risk patients. His perspective is that CRd can be an option across the board for all frontline patients. 

Antonio Palumbo is very much focused upon the need to assess the "fitness" of patients at diagnosis including the presence or absence of so called "co-morbidities"--other medical problems and other needed medications. Antonio's protocol results also support the value of multi-drug combinations and even high dose therapy for "fit" elderly patients. So there was a sense that the Rd two drug combos is a simple excellent option, but in fit patients it is certainly reasonable to explore the value of more aggressive combination therapies.

The Role of Maintenance

The greatest controversy emerged over the role of maintenance. The controversy at ASH this year was triggered by the presentation by Michel Attal from the IFM team, who presented the longer-term results of Revlimid maintenance following autologous stem cell transplant. As had been expected, the presentation showed improved length of remission with Revlimid maintenance, but no overall survival benefit. There have been many speculations about reasons for the lack of survival benefit, including use of 2 months of Revlimid consolidation after transplant given to all patients (including those with no maintenance). 

But what brought a flood of myeloma experts to the microphone for questions at ASH was an analysis which showed dramatically better outcomes for patients on placebo (no Revlimid maintenance) at the point of first relapse. As pointed out by Dr. Shaji Kumar from the Mayo Clinic, this was a flawed analysis in an already flawed study. But many issues were left unresolved at the time of the presentation. Other abstracts strongly affirmed the value of Revlimid maintenance (in addition to continuous or extended use in the frontline setting) using meta analyses of available trial results. 

Joseph Mikhael said he does not routinely recommend maintenance because of the confusion surrounding the data. Conversely, Antonio Palumbo, Ola Landgren, and I said we feel that the preponderance of data supports the use of maintenance, which we feel comfortable recommending, certainly from the standpoint of efficacy. 

Minimal Residual Disease -- Is It Important?

There was unanimity on the subject of the importance of Minimal Residual Disease.  MRD is important. We need to now measure MRD in a standardized fashion and use the information to compare results in randomized trials and to direct treatment to achieve MRD-Zero in trials designed to seek a cure.

Thus the central concepts of the Black Swan Research Initiative® are being enthusiastically endorsed by the myeloma expert community. 2014 is indeed going to be exciting as we see the research results and the rapid process to achieving a cure.

New Drugs -- Which Will Make an Impact?

I listed 8 drugs which are most promising from the 2013 ASH presentations: anti-CD38 monoclonal antibodies (daratumumab and SAR650984); MLN 9708; ARRY 520; ACY 1215; Selinexor; anti-CD138; panobinostat; and bendamustine. There were interesting discussion points about all 8 compounds. However, everyone agreed that the anti-CD38 compounds are both the most exciting and most likely to add a new mechanism of action to our current combination approaches.

Joe, for the first time, presented the more detailed results with SAR antibody as a single agent. About half of the patients responded, some with very deep responses (greater than VGPR).

Follow-up results with the daratumumab antibody were also presented showing substantial benefit. There is great anticipation that even more promising results are to come with anti-CD38 trials moving forward rapidly in 2014.

The IMWG Conference Series at ASH closed with a follow-up from Joseph Mikhael about the new acronym, "Lobster" that he proposed at our last debate. He now suggests that the new acronym will be "CRAB-LEGS" to identify patients with early active myeloma who do not yet have "CRAB" features. So stay tuned to hear more details about this. 

And finally, it was realized that if progress in treatment continues at the current pace, myeloma experts are in danger of putting themselves out of a job. It was agreed that if both doctors and patients end up on permanent vacation in Hawaii, it will be fine!

So here is to further improved outcomes in 2014 and an improving future for all myeloma patients everywhere!

A more comprehensive overview will be provided on the "Post-ASH" teleconference scheduled for January 16, 2014. Register here: http://bestofash2013.myeloma.org/ 

To view the archived video of the IMWG Conference Series: Making Sense of Treatment click here: http://bit.ly/1bHvql7

Dr. Durie sincerely appreciates and reads all comments left here. However, he cannot answer specific medical questions and encourages readers to contact the trained IMF Hotline staff instead. Specific medical questions posted here will be forwarded to the IMF Hotline. Questions sent to the Hotline are answered with input from Dr. Durie and/or other scientific advisors and IMWG members as appropriate. To contact the IMF Hotline, call  800-452-CURE, toll-free in the US and Canada, or send an email to hotline@myeloma.org. Hotline hours are 9 am to 4 pm PST. Thank you.

8 Comments

Thank you yet again for all you do for the MM community and patients in particular.

I didn't see any indication that the use of multiple antibodies targeting both CD38 and CD138 might be an option. These therapies appear to be well tolerated on their own or in combination with Revlimid. Might they also be tolerated in combination with each other?

It is my understanding that it is common for MM to express a few antibodies and often they are both CD38 & CD138 (a potential population which might show significant synergistic efficacy from such a combination).

Being a bit of math geek I see that with all the drugs currently available there is no way to find the best combination via clinical trials. There are just too many potential combinations. I am sure you are also aware that the only statistic that really matters pertains to the patient in question.

Has there been any significant movement on patient specific therapy guidance?

Thanks again!
Scott

I was diagnosed with MM in 2008; I never had any fractures. I had an autogolus stem cell transplant. For 6 months prior to transplant, I was on Rev and Dex. I am still in remission. I have never been on any maintenance drugs. I have CBC and M-protein blood tests every 6 months. I have had one bone marrow draw/biopsy since 2008 transplant. I am age 70 now.

I take Vit D and Calcium and B-12.

Do you have any recommendations for further post-transplant maintenance and/or diagnosis?

I still work part time (at desk job). I snow ski and play tennis and do lite weights 3 times a week.

Phone 360 773 5199

Great news on the research .
I was diagnosed 4 years ago with Stage 1. Didn't like the sound of watchful waiting, or some such phrase.
Began taking PolyMVA along with Curcumin,COQ10, Omega 3, 10,000 IU D3, liver pills, cut out sugar in my diet ( as much as you can in today's food) and others. After 9 months my diagnosis was changed to Smoldering.
When I learned about the results of the Spanish trial for High Risk Smoldering myeloma presented in July 2013 in the NEMJ, I talked to my Oncologist, and have started the regimen of 25 MG Rev for 21 days, and Dex 20 MG, once a week. No side effects for either drug.
Am now looking into Immune system treatments.
I'm a 71 year old male of normal height and weight for my size.
I believe it is important to be proactive, since, after all, it's my life.

Thanks for reading,

Jim Swelgin
Fallbrook, CA.

any news on pomalyst?...s theoly drug that has helped me and it is relly helping!

Thanks for the excellent review of ASH. I had some questions with regard to frontline therapy. Dr. Mikhael made the point that CyBorD had less side effects than PI/IMID/DEX and no one seemed to challenge him. I have seen early studies that around 10% of patients had a Grade 3 or 4 heart failure with Kyprolis. I also saw the the rate of PN is about 30-40% with Kyprolis/REV/DEX. Also taking into account the short overall survival of patients that are resistant and not responding to IMIDs and PI's I think CyBorD sounds like the better choice. Kyprolis/REV/DEX induction is not a cure and using it early starts building resistance to PI's and IMIDs. IMO myeloma therapy should be viewed as a marathon and not a sprint. Starting to make a patient resistant to IMIDs and PI's as soon as therapy starts seems like a major disadvantage to using a PI/IMID/DEX combo upfront. I would be most interested what your thoughts are on that subject?

I have recently gone out remission and my protein has started to climb to the point that I will start on revlimid and dex this tuesday. I have 4;14 iga myeloma and wonder if any of the new drugs mentioned have better results for intermediate risk patients

I am a multiple myeloma survivor (7 1/2 years) who has not been able to find a drug that I could stay on for any length of time. I have had two stem cell transplants (tandem) which brought me a remission of two years and nine months. I have also been on Velcade, Revlimid, Carfilmazib, and a variety of different medications. Both Velcade and Revlimid worked but I was not able to tolerate them. Most recently I have participated in a clinical trial of the new monoclonal antibody, SAR650984 which worked for seven and a half months and then stopped working. I have stopped even hoping for a cure and would just like to find a medicine that would bring me into remission and keep me there on a long-term basis. For me, Minimum Residual Disease is a concept with very little meaning, as is the whole notion of cure. I have donated to the IMF in the past and would like to do so again, but I want to know that my money is going to find new drugs that will help people like me who are less interested in knowing if they are "cured" than in just surviving on a day-by-day basis.

Australian university (UNSW)have recently found a way of collapsing the structure of cancer cells without killing the heart. Killing the heart and therefore the patient apparently caused this line of research to be abandoned around 25 years ago. 5 compounds are now being tested in the US for toxicity. A drug may be available as early as 2015. See article http://www.news.com.au/lifestyle/health/breakthrough-cancer-cell-treatment-from-the-university-of-nsw-offers-new-hope/story-fneuzlbd-1226697364320 Is there any potential relevance of this approach to mm? Are any researchers in the mm area starting to look at this avenue? If so, who?

Keep up the good work - Guy

Leave a comment

To subscribe to this blog, enter your email address below: